Lek presents ScienceBEAT, a new scientific and professional event for young talent
- Lek, a Sandoz company, presents ScienceBEAT, a new, cutting-edge scientific and professional event for promising natural sciences and business students from Slovenia and abroad.
- Participants will have the unique opportunity to build on their knowledge and expand their professional network by working with world-class scientists and entrepreneurs – including a Nobel laureate and a former Apple executive.
- The event is the result of Lek's close cooperation with academia, which has once again shown to be an added value in our efforts to develop new, innovative and future-oriented projects.
Lek, a Sandoz company, in cooperation with the Ljubljana University Incubator, the Spirit agency, the University of Ljubljana, the University of Maribor and the University of Primorska, is organizing ScienceBEAT, a new innovative scientific and professional event. The event, which will take place this year between September 7 and 10 in Ljubljana and Lendava, is a unique opportunity for young talents to join a global network of professional excellence in science and entrepreneurship and a great springboard for their careers.
30 selected participants will gain a valuable insight into the trends and challenges of the modern pharmaceutical industry and feel the beat of a global pharmaceutical company that is a leader in the development and production of biosimilars and generic pharmaceuticals. Applications are open until June 18, 2023 to students in their final year of undergraduate studies, as well as to master's, doctoral and post-doctoral students in natural sciences and business from Slovenia and abroad.
A carefully designed program offering opportunities for professional and personal growth
The event will feature a wide range of professional activities designed for networking, promoting knowledge transfer and learning from leading scientists, researchers and entrepreneurs. The keynote speakers will be: British geneticist and cell biologist Sir Paul Nurse, Nobel Prize winner in Physiology or Medicine for his groundbreaking research on the cell cycle, and Andy Baynes, former Apple, Nest and Google executive, entrepreneur and product design and innovation specialist.
The four-day program will also include a tour of Lek's sites in Ljubljana and Lendava, where participants will learn about the work of leading Lek and Sandoz scientists. They will also experience the inspiring organizational culture based on inclusiveness, fairness and diversity, which motivates employees to give their best. One of the highlights of the event will be a group work session on a pharmaceutical business challenge, which will give participants hands-on experience and the opportunity to showcase their practical knowledge.
The professional side of the event will be complemented by a range of activities aimed at developing participants' social skills, getting to know the local community’s culture and promoting networking in a relaxed and informal environment.
The very best in science and entrepreneurship from around the world
ScienceBEAT is the result of an excellent collaboration between business and academia, which Lek has fostered since its inception. Through various projects, Lek reaches out to young, promising students and professionals from various fields, who are given the opportunity to work with international experts within Sandoz's global network, acquire new knowledge and skills, unleash their talents and creativity, and build their careers. With this goal in mind, we have been working with scientific, research and educational institutions for many years. With ScienceBEAT, we want to further strengthen our partnership with the academic community and offer exceptional talent a unique opportunity to connect with world-class scientists, researchers and entrepreneurs," commented Robert Ljoljo, President of the Board of Management of Lek and Sandoz Country President Slovenia, upon announcing the event.
Jure Vajs, Head Strategic Programs at Lek and Head of the ScienceBEAT organization committee, added: "ScienceBEAT is a unique opportunity for young talent in Slovenia, bringing together the world's best in science and entrepreneurship. It is the result of the joint efforts of Lek and its outstanding partners and establishes the foundations for new, forward-looking ways of working and collaborating between science and business in Slovenia. The program is designed with outstanding individuals from diverse backgrounds and academic disciplines in mind, who will bring diversity and excellence to the event and shape the future with us."
More information about the event is available at www.lek.si/sciencebeat
Novartis is the leading provider of medicines in Slovenia, where Lek d.d., Novartis Pharma Services Inc. and Sandoz d.d., operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Operations, Global DrugDevelopment and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Novartis invested in Slovenia more than EUR 3.4 billion since 2003.
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2022 sales of USD 9.2 billion.
Novartis is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 106,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at https://www.novartis.com
This press release contains statements and forecasts of future business operations. The forecasts include estimates based on all the information currently available to us. Should these forecasts prove unreliable, the actual results of business operations could be different from those expected.
For further information, please contact:
Head Corporate Affairs
Lek Pharmaceuticals d.d.
Telephone: 01 580 22 43